{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003766","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.424586+00:00","generated_at":"2026-06-19T05:12:20.739556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TransMedics Q4 revenue $31.4M (+225% YoY); guides FY2023 $138-145M","bullets":["Total revenue $31.4M in Q4 2022, up 225% from $9.7M in Q4 2021; full-year revenue $93.5M (+209%).","Net loss narrowed to $6.7M in Q4 2022 from $12.7M; full-year net loss $36.2M vs $44.2M in 2021.","Gross margin 66% in Q4 vs 72% prior year; full-year gross margin flat at 70%.","Cash and equivalents $201.2M as of Dec 31, 2022; operating expenses rose to $27.5M in Q4.","FY2023 revenue guidance $138-145M (48-55% growth); appointed Nick Corcoran as SVP Supply Chain in Jan 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003766","json":"https://secwatch.observer/filing/0000950170-23-003766.json","markdown":"https://secwatch.observer/filing/0000950170-23-003766.md","text":"https://secwatch.observer/filing/0000950170-23-003766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023003766/0000950170-23-003766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023003766/tmdx-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T05:12:20.739556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3199fcb79cbd0058f0a755a91d6022f6b5a70e52","claim":"TransMedics Group, Inc. reported Full year 2023 results: revenue $138 million to $145 million. Guidance initiated.","evidence_excerpt":"TransMedics expects total revenue for full-year 2023 to be in the range of $138 million to $145 million, which represents 48% to 55% growth compared to the company’s prior year revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023003766/0000950170-23-003766-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year 2023"},{"label":"Revenue","value":"$138 million to $145 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}